Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

BioXcel Therapeutics stock

BTAI
US09075P1057
A2JF20

Price

3.37
Today +/-
+0.58
Today %
+20.62 %

BioXcel Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the BioXcel Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the BioXcel Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the BioXcel Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze BioXcel Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

BioXcel Therapeutics Stock Price History

DateBioXcel Therapeutics Price
3/6/20253.37 undefined
3/5/20252.74 undefined
3/4/20252.73 undefined
3/3/20252.70 undefined
3/2/20253.75 undefined
2/27/20252.16 undefined
2/26/20251.73 undefined
2/25/20251.80 undefined
2/24/20251.80 undefined
2/23/20251.97 undefined
2/20/20252.13 undefined
2/19/20252.30 undefined
2/18/20252.38 undefined
2/17/20252.27 undefined
2/13/20252.31 undefined
2/12/20252.38 undefined
2/11/20252.81 undefined
2/10/20252.55 undefined
2/9/20252.98 undefined
2/6/20252.64 undefined

BioXcel Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BioXcel Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioXcel Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioXcel Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BioXcel Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BioXcel Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BioXcel Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioXcel Therapeutics’s growth potential.

BioXcel Therapeutics Revenue, EBIT and net profit per share

DateBioXcel Therapeutics RevenueBioXcel Therapeutics EBITBioXcel Therapeutics Net Income
2030e84.66 M undefined0 undefined0 undefined
2029e169.47 M undefined48.81 M undefined1.28 M undefined
2028e108.68 M undefined1.22 M undefined-172,890.01 undefined
2027e58.85 M undefined-34.63 M undefined-2.94 M undefined
2026e15.49 M undefined-68.23 M undefined-49.66 M undefined
2025e4.16 M undefined-70 M undefined-67.27 M undefined
2024e2.83 M undefined-75.31 M undefined-94.61 M undefined
20231.38 M undefined-167.62 M undefined-179.05 M undefined
2022380,000 undefined-159.65 M undefined-165.76 M undefined
20210 undefined-106.94 M undefined-106.93 M undefined
20200 undefined-82.3 M undefined-82.17 M undefined
20190 undefined-33.6 M undefined-32.97 M undefined
20180 undefined-19.96 M undefined-19.27 M undefined
20170 undefined-4.54 M undefined-4.54 M undefined
20160 undefined-2.12 M undefined-2.12 M undefined
20150 undefined-640,000 undefined-640,000 undefined

BioXcel Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00000000124155810816984
---------100.00100.00275.00286.6786.2156.48-50.30
----------------
0000000000000000
0-2,000-4,000-19,000-32,000-82,000-106,000-165,000-179,000-94,000-67,000-49,000-2,00001,0000
--100.00375.0068.42156.2529.2755.668.48-47.49-28.72-26.87-95.92---
15.6515.6515.6514.5716.2921.6826.3728.021.820000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The BioXcel Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the BioXcel Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
000.942.632.4213.1233193.765.22
000000020071
000000000
000000021.99
0000.61.73.93.96.94.86
000.943.234.1217236.9202.872.14
0000.32.22.82.52.11.47
000000000
000000000
000000000
000000000
0050010010010010090087
000.50.42.32.92.631.56
001.443.636.4219.9239.5205.873.7
                 
0000000030
003.562.683.6345.5467.4488.3534.06
00-4.5-23.7-56.7-138.9-245.8-411.5-590.6
-0.2-0.30000000
000000000
-0.2-0.3-138.926.9206.6221.676.8-56.51
0.10.30.41.6544.710.213.65
0.10.113.13.3711.522.113.39
005000200900500600223
00400000000
000000000
0.20.42.34.78.511.916.732.927.27
000000093.1100.6
000000000
000011.41.13.12.35
000011.41.196.2102.94
0.20.42.34.79.513.317.8129.1130.21
00.11.343.636.4219.9239.4205.973.7
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of BioXcel Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand BioXcel Therapeutics's financial health and stability.

Assets

BioXcel Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that BioXcel Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of BioXcel Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into BioXcel Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
0-2-4-19-32-82-106-165-179
000000000
000000000
0002214102
0136629383621
000000027
000000000
0-1-2-13-27-66-82-135-155
000000000
000000000
000000000
000000000
0000000980
0025617247102027
01355172471029626
01,00000000-2,000-1,000
000000000
00041-1018019-39-128
-0.28-1.29-2.2-13.85-27.97-66.67-82.6-135.48-155.03
000000000

BioXcel Therapeutics stock margins

The BioXcel Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioXcel Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioXcel Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BioXcel Therapeutics's sales revenue. A higher gross margin percentage indicates that the BioXcel Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BioXcel Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BioXcel Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioXcel Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioXcel Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioXcel Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BioXcel Therapeutics Margin History

BioXcel Therapeutics Gross marginBioXcel Therapeutics Profit marginBioXcel Therapeutics EBIT marginBioXcel Therapeutics Profit margin
2030e8.7 %0 %0 %
2029e8.7 %28.8 %0.75 %
2028e8.7 %1.13 %-0.16 %
2027e8.7 %-58.84 %-4.99 %
2026e8.7 %-440.59 %-320.69 %
2025e8.7 %-1,681.07 %-1,615.55 %
2024e8.7 %-2,657.46 %-3,338.23 %
20238.7 %-12,146.3 %-12,974.86 %
202294.74 %-42,013.16 %-43,621.05 %
20218.7 %0 %0 %
20208.7 %0 %0 %
20198.7 %0 %0 %
20188.7 %0 %0 %
20178.7 %0 %0 %
20168.7 %0 %0 %
20158.7 %0 %0 %

BioXcel Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The BioXcel Therapeutics earnings per share therefore indicates how much revenue BioXcel Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioXcel Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioXcel Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioXcel Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioXcel Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioXcel Therapeutics Revenue, EBIT and net profit per share

DateBioXcel Therapeutics Sales per ShareBioXcel Therapeutics EBIT per shareBioXcel Therapeutics Earnings per Share
2030e24.97 undefined0 undefined0 undefined
2029e49.99 undefined0 undefined0.38 undefined
2028e32.06 undefined0 undefined-0.05 undefined
2027e17.36 undefined0 undefined-0.87 undefined
2026e4.57 undefined0 undefined-14.65 undefined
2025e1.23 undefined0 undefined-19.84 undefined
2024e0.84 undefined0 undefined-27.91 undefined
20230.76 undefined-92.07 undefined-98.35 undefined
20220.01 undefined-5.7 undefined-5.92 undefined
20210 undefined-4.06 undefined-4.05 undefined
20200 undefined-3.8 undefined-3.79 undefined
20190 undefined-2.06 undefined-2.02 undefined
20180 undefined-1.37 undefined-1.32 undefined
20170 undefined-0.29 undefined-0.29 undefined
20160 undefined-0.14 undefined-0.14 undefined
20150 undefined-0.04 undefined-0.04 undefined

BioXcel Therapeutics business model

BioXcel Therapeutics Inc. is a biotechnology company based in New Haven, CT, USA, focused on the development of novel therapeutics for severe neurological and psychiatric diseases as well as cancer. The company was founded in 2017 and is listed on the NASDAQ stock exchange. The founding of BioXcel Therapeutics Inc. was based on the concept that the combination of state-of-the-art data analytics technologies such as artificial intelligence (AI) and big data analysis with traditional biomedical approaches can open new opportunities in the field of drug discovery and development. The company utilizes its extensive database of clinical, genetic, molecular, and other data to identify targets and molecules that show promise for treating severe diseases. The business model of BioXcel Therapeutics Inc. includes both internal development and a licensing and partnership strategy. The company is working on various projects currently in different stages of clinical development. The key therapeutics currently in the company's pipeline include BXCL501, BXCL701, and BXCL702. BXCL501 is a novel treatment approach for acute anxiety and agitation in patients with schizophrenia, bipolar disorders, and Alzheimer's disease. The drug is based on a combination of DEX, an alpha-2 agonist, and melatonin. The company is currently planning a Phase III trial for BXCL501. BXCL701 is an oral immunoncology drug based on the inhibition of interleukin-12 and -23 and has the potential to treat various types of cancer. The drug is still in the clinical development phase. BXCL702 is a novel approach to treating pain in patients with peripheral neuropathic pain. The drug is currently in the preclinical development phase. BioXcel Therapeutics also operates a licensing and partnership strategy for drug development and commercialization. In November 2019, the company entered into an exclusive global licensing agreement with Nocion Therapeutics, a company specializing in the development of drugs for localized pain. Under this agreement, BioXcel Therapeutics will pursue the development and commercialization of Nocion's technology platform for the delivery of anesthetic drugs to patients with peripheral neuropathy. The company has also partnered with the Zambon Group, a leading European company in pharmaceutical and biotechnology research and development, and has entered into a research collaboration with Eisai Co. Ltd. BioXcel Therapeutics is an innovative company that combines the benefits of state-of-the-art data analytics technologies with traditional biomedical approaches to develop therapeutics for severe neurological and psychiatric diseases as well as cancer. The company has a well-stocked pipeline of promising drugs in various stages of clinical development and an effective licensing and partnership strategy that allows for further growth. BioXcel Therapeutics is one of the most popular companies on Eulerpool.com.

BioXcel Therapeutics SWOT Analysis

Strengths

BioXcel Therapeutics Inc (BioXcel) has several strengths that contribute to its success in the market. Firstly, the company focuses on innovative approaches to drug development, utilizing artificial intelligence (AI) and machine learning technologies. This allows for faster and more efficient identification of potential drug candidates, leading to faster development timelines and reduced costs. Additionally, BioXcel's strong intellectual property portfolio provides a competitive advantage, protecting its innovative technologies and discoveries.

Weaknesses

However, BioXcel also faces certain weaknesses that could hinder its growth. One weakness is its relatively limited financial resources. As a smaller biotech company, it may struggle to compete with larger players that have significantly higher financial capabilities. This could potentially restrict BioXcel's ability to fully explore its drug development pipeline and expand its operations. Another weakness is the company's heavy reliance on AI and machine learning technologies. While these technologies offer great potential, any errors or limitations in these algorithms could have significant consequences on the accuracy and effectiveness of BioXcel's drug discovery process.

Opportunities

Despite the challenges, there are several opportunities that BioXcel can capitalize on. The increasing demand for personalized medicine and targeted therapies presents a significant market opportunity for the company. By leveraging its AI capabilities, BioXcel can develop tailored treatments that address specific patient populations, potentially improving treatment outcomes and gaining a competitive edge. Furthermore, collaborations and partnerships with established pharmaceutical companies can offer BioXcel access to additional resources and expertise, enabling accelerated research and development activities.

Threats

BioXcel operates in a highly competitive industry, which brings several threats that need to be considered. One major threat is the regulatory and legal environment. The pharmaceutical industry is subject to stringent regulations and compliance requirements, which could slow down BioXcel's drug approval process and increase costs. Moreover, there is always a risk of potential intellectual property disputes, as competitors may challenge BioXcel's patents and technologies. Additionally, uncertainties in healthcare policies and reimbursement systems can impact the market acceptance and pricing of BioXcel's therapies.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

BioXcel Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

BioXcel Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

BioXcel Therapeutics shares outstanding

The number of shares was BioXcel Therapeutics in 2024 — This indicates how many shares 1.821 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioXcel Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioXcel Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioXcel Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioXcel Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioXcel Therapeutics stock splits

In BioXcel Therapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for BioXcel Therapeutics.

BioXcel Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-8.84 -5.12  (42.08 %)2024 Q3
6/30/2024-11.59 -3.36  (71 %)2024 Q2
3/31/2024-0.71 -0.87  (-22.14 %)2024 Q1
12/31/2023-0.93 -0.76  (18.12 %)2023 Q4
9/30/2023-1.33 -1.72  (-29.31 %)2023 Q3
6/30/2023-1.79 -1.83  (-2.47 %)2023 Q2
3/31/2023-1.65 -1.84  (-11.48 %)2023 Q1
12/31/2022-1.48 -1.95  (-32.18 %)2022 Q4
9/30/2022-1.38 -1.49  (-8.35 %)2022 Q3
6/30/2022-1.24 -1.35  (-8.56 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the BioXcel Therapeutics stock

Eulerpool World ESG Rating (EESG©)

12/ 100

🌱 Environment

2

👫 Social

23

🏛️ Governance

11

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

BioXcel Therapeutics shareholders

%
Name
Stocks
Change
Date
14.16944 % Bioxcel Corp480,344-53,8286/6/2024
2.35416 % UBS Financial Services, Inc.79,80678,97912/31/2024
0.68962 % BlackRock Institutional Trust Company, N.A.23,3781,13312/31/2024
0.57516 % Geode Capital Management, L.L.C.19,49887012/31/2024
0.38678 % Mueller (Peter)13,112-1,42511/30/2024
0.33991 % Votruba (Michal)11,523011/30/2024
0.29965 % Mack (David J)10,1581,6931/31/2025
0.14224 % State Street Global Advisors (US)4,822012/31/2024
0.13625 % Northern Trust Investments, Inc.4,6192,07412/31/2024
0.12906 % Saint Olive Gestion4,375012/31/2024
1
2
3
4
5
...
10

BioXcel Therapeutics Executives and Management Board

Dr. Vimal Mehta

(62)
BioXcel Therapeutics President, Chief Executive Officer, Director (since 2017)
Compensation 4.56 M

Mr. Matthew Wiley

(51)
BioXcel Therapeutics Senior Vice President, Chief Commercial Officer
Compensation 1.93 M

Mr. Javier Rodriguez

(51)
BioXcel Therapeutics Senior Vice President, Chief Legal Officer, Corporate Secretary
Compensation 1.22 M

Dr. Frank Yocca

(67)
BioXcel Therapeutics Senior Vice President, Chief Scientific Officer
Compensation 1.15 M

Dr. Vincent O'Neill

(54)
BioXcel Therapeutics Executive Vice President, Chief of Product Development and Medical Officer
Compensation 510,167
1
2
3

Most common questions regarding BioXcel Therapeutics

What values and corporate philosophy does BioXcel Therapeutics represent?

BioXcel Therapeutics Inc represents a strong commitment to innovation and patient-centric approaches in the field of biopharmaceuticals. The company values scientific excellence, integrity, and ethical conduct in its pursuit of developing novel therapies. With a focus on leveraging artificial intelligence (AI) and big data analytics, BioXcel Therapeutics aims to revolutionize drug discovery and improve patient outcomes. The company actively collaborates with leading institutions to advance research and development efforts. Through its dedication to transformative science and a patient-focused corporate philosophy, BioXcel Therapeutics Inc strives to bring innovative treatments to market and make a positive impact on global healthcare.

In which countries and regions is BioXcel Therapeutics primarily present?

BioXcel Therapeutics Inc is primarily present in the United States.

What significant milestones has the company BioXcel Therapeutics achieved?

BioXcel Therapeutics Inc has achieved several significant milestones. The company successfully completed a Phase 1b clinical trial for its lead product candidate, BXCL501, in patients with schizophrenia and bipolar disorder. In addition, BioXcel Therapeutics received Fast Track designation from the U.S. Food and Drug Administration for the development of BXCL501. The company also progressed the clinical development of BXCL701, an immuno-oncology therapy, by initiating Phase 1b/2 clinical trials in prostate cancer and pancreatic cancer. Furthermore, BioXcel Therapeutics has formed collaborations and partnerships with renowned academic institutions and pharmaceutical companies to explore the full potential of its innovative therapies.

What is the history and background of the company BioXcel Therapeutics?

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines using artificial intelligence. Founded in 2017, the company utilizes its proprietary innovation platform to engineer drugs targeting unmet medical needs. BioXcel Therapeutics combines data-driven insights with traditional drug development techniques to effectively identify and advance innovative therapies. With a strategic focus on neurological and immuno-oncology disorders, BioXcel Therapeutics aims to improve patient outcomes through its robust pipeline of product candidates. The company has established collaborations with renowned institutions and continues to push the boundaries of drug discovery and development through its cutting-edge approach.

Who are the main competitors of BioXcel Therapeutics in the market?

The main competitors of BioXcel Therapeutics Inc in the market include Genentech, Roche, Novartis, and Pfizer.

In which industries is BioXcel Therapeutics primarily active?

BioXcel Therapeutics Inc is primarily active in the healthcare and biotechnology industries.

What is the business model of BioXcel Therapeutics?

BioXcel Therapeutics Inc is a biopharmaceutical company that focuses on developing transformative medicines using artificial intelligence (AI) and data analytics. The company's business model revolves around identifying innovative drug candidates and advancing them through preclinical and clinical trials. By leveraging AI algorithms, BioXcel Therapeutics aims to rapidly discover and develop therapies for unmet medical needs. Through strategic collaborations and partnerships, the company aims to commercialize these novel treatments. With its unique approach combining AI technology and pharmaceutical expertise, BioXcel Therapeutics Inc strives to revolutionize the way drugs are discovered and developed, ultimately improving patient outcomes.

What is the P/E ratio of BioXcel Therapeutics 2025?

The BioXcel Therapeutics P/E ratio is -0.09.

What is the P/S ratio of BioXcel Therapeutics 2025?

The BioXcel Therapeutics P/S ratio is 1.47.

What is the Quality Investing of BioXcel Therapeutics?

The Quality Investing for BioXcel Therapeutics is 4/10.

What is the revenue of BioXcel Therapeutics 2025?

The expected BioXcel Therapeutics revenue is 4.16 M USD.

How high is the profit of BioXcel Therapeutics 2025?

The expected BioXcel Therapeutics profit is -67.27 M USD.

What is the business model of BioXcel Therapeutics

BioXcel Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of novel therapies for severe diseases. The company utilizes an innovative data science-based approach to identify drug candidates and rapidly develop precision medicine. The company has developed its technology platform BXCL501, which is based on pharmacological sedation and analgesia technology. This is a unique method for rapidly developing effective and precise medications that target specific biological target molecules. Another important aspect of the company is the BXCL701 platform, which focuses on immuno-oncology. BioXcel Therapeutics utilizes its specialized technologies to identify and develop drug candidates for various stages of severe diseases. This includes CNS disorders, psychoactive disorders, immuno-oncology, neurodegenerative diseases, and other rare diseases. The company also offers a wide range of medications, including BXCL501 (Dexmedetomidine), BXCL701, BXCL702, and BXCL501 (Methylphenidate). The BXCL501 platform aims to prevent and treat psychoactive disorders and anxiety, while BXCL701 focuses on preventing and stopping tumors in the human body. BioXcel Therapeutics has built a pipeline of multiple international investigational products and development programs focusing on groundbreaking therapies. This is aimed at meeting the demands of patients in the coming years. With the enormous potential of innovative therapies, the company is focused on expansion to further diversify its focus and expand its offering of therapeutic solutions. Conclusion: BioXcel Therapeutics Inc is a company that plays a leading role in the discovery and development of innovative therapeutics. By using data science technologies and focusing on precision medicine approaches, the company efficiently identifies drug candidates targeting biological target molecules to treat severe diseases. Through its BXCL501 and BXCL701 platforms, it offers a broad range of medications to further strengthen its leadership position in the therapeutics field. With a solid portfolio of development programs and international investigational products, the company is focused on expansion and continues to prioritize the development of promising new therapies to meet the needs of patients.

What is the BioXcel Therapeutics dividend?

BioXcel Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does BioXcel Therapeutics pay dividends?

The dividend cannot currently be calculated for BioXcel Therapeutics or the company does not pay out a dividend.

What is the BioXcel Therapeutics ISIN?

The ISIN of BioXcel Therapeutics is US09075P1057.

What is the BioXcel Therapeutics WKN?

The WKN of BioXcel Therapeutics is A2JF20.

What is the BioXcel Therapeutics ticker?

The ticker of BioXcel Therapeutics is BTAI.

How much dividend does BioXcel Therapeutics pay?

Over the past 12 months, BioXcel Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioXcel Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of BioXcel Therapeutics?

The current dividend yield of BioXcel Therapeutics is .

When does BioXcel Therapeutics pay dividends?

BioXcel Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioXcel Therapeutics?

BioXcel Therapeutics paid dividends every year for the past 0 years.

What is the dividend of BioXcel Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioXcel Therapeutics located?

BioXcel Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioXcel Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioXcel Therapeutics from 3/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/8/2025.

When did BioXcel Therapeutics pay the last dividend?

The last dividend was paid out on 3/8/2025.

What was the dividend of BioXcel Therapeutics in the year 2024?

In the year 2024, BioXcel Therapeutics distributed 0 USD as dividends.

In which currency does BioXcel Therapeutics pay out the dividend?

The dividends of BioXcel Therapeutics are distributed in USD.

All fundamentals about BioXcel Therapeutics

Our stock analysis for BioXcel Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioXcel Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.